Cite
Successful use of rituximab for refractory hemophagocytic lymphohistiocytosis in a melanoma patient treated with targeted therapy.
MLA
Tejedor, Ines, et al. “Successful Use of Rituximab for Refractory Hemophagocytic Lymphohistiocytosis in a Melanoma Patient Treated with Targeted Therapy.” Melanoma Research, vol. 32, no. 6, Dec. 2022, pp. 485–87. EBSCOhost, https://doi.org/10.1097/CMR.0000000000000845.
APA
Tejedor, I., Tedbirt, B., Carvalho, P., Duval-Modeste, A. B., Joly, P., & Hébert, V. (2022). Successful use of rituximab for refractory hemophagocytic lymphohistiocytosis in a melanoma patient treated with targeted therapy. Melanoma Research, 32(6), 485–487. https://doi.org/10.1097/CMR.0000000000000845
Chicago
Tejedor, Ines, Billal Tedbirt, Priscille Carvalho, Anne Bénédicte Duval-Modeste, Pascal Joly, and Vivien Hébert. 2022. “Successful Use of Rituximab for Refractory Hemophagocytic Lymphohistiocytosis in a Melanoma Patient Treated with Targeted Therapy.” Melanoma Research 32 (6): 485–87. doi:10.1097/CMR.0000000000000845.